Article
Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Cancer chemotherapy and pharmacology - 1 Nov 2015
Queckenberg Christian, Erlinghagen V, Baken B C M, Van Os S H G, Wargenau M, Kubeš V, Peroutka R, Novotný V, Fuhr U
Abstract excerpt
PURPOSE: To describe concentration versus time profiles of capecitabine and its metabolites 5'-DFUR, 5'-DFCR and 5-FU, depending on tablet formulation and on frequent and/or relevant genetic polymorphisms of cytidine deaminase, dihydropyrimidine dehydrogenase, thymidylate synthase and methylenetetrahydrofolate reductase (MTHFR). METHODS: In 46 cancer patients on chronic capecitabine treatment, who voluntarily...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.